Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYCETIN versus TIMENTIN IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYCETIN versus TIMENTIN IN PLASTIC CONTAINER.
CHLOROMYCETIN vs TIMENTIN IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
Timentin is a combination of ticarcillin, a penicillin-class beta-lactam antibiotic, and clavulanate, a beta-lactamase inhibitor. Ticarcillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), while clavulanate irreversibly inhibits beta-lactamases, preventing degradation of ticarcillin.
50-100 mg/kg/day IV divided every 6 hours; maximum 4 g/day. Topical: apply to affected area 2-4 times daily.
3.1 g (ticarcillin 3 g + clavulanate 0.1 g) IV every 4 to 6 hours; maximum 18 g per day.
None Documented
None Documented
1.5-4 hours in adults; prolonged to 3-7 hours in neonates and 4-12 hours in hepatic impairment; clinical context: dose adjustment required in liver disease.
Ticarcillin: ~1.2 hours; Clavulanate: ~1.0 hours. Prolonged in renal impairment (ticarcillin up to 15 hours in ESRD).
Renal: 5-10% unchanged; hepatic glucuronidation (90%) followed by renal elimination of metabolites; small biliary excretion (<5%) and fecal elimination.
Renal: ~70-80% of ticarcillin and ~60-70% of clavulanate excreted unchanged in urine within 6 hours. Biliary/fecal: Minor (<5%).
Category C
Category C
Antibiotic
Antibiotic